A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome

Jacob H. Rand, Xiao Xuan Wu, Lucia R. Wolgast, Victor Lei, Edward M. Conway

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction The antiphospholipid syndrome (APS) is marked by autoantibodies that recognize anionic phospholipids in a cofactor-dependent manner. A role for complement has been implicated in the pathophysiology, however, elevations of complement activation markers have not been consistently demonstrated in clinical studies. We therefore designed a proof-of-principle study to determine whether complement activation might be detectable in APS by first exposing plasmas to phospholipid vesicles. Methods We examined complement activation markers in patients with APS, non-APS thrombosis, systemic lupus erythematosus, cancer, patients with antiphospholipid antibodies without thrombosis (APL) and healthy controls. Direct measurements of plasma C5a and sC5b-9 levels were compared to levels that were generated in normal serum by phospholipid vesicles that had been pre-incubated with the same plasmas. We then determined the effects of the C5 inhibitor, eculizumab, examined the complement pathways involved, and determined whether the effects could be reproduced with purified IgGs and β2-glycoprotein I (β2GPI). Results Plasma levels of C5a and sC5b-9 were higher, but not significantly increased in APS patients compared to healthy controls. In contrast, phospholipid vesicles pre-incubated with APS plasmas generated significantly higher levels than healthy controls and the other groups, except for APL patients. Complement activation was abrogated by addition of eculizumab. The results with substrate sera indicated that the alternative and classical/lectin pathways were involved. The results were reproducible with purified IgGs and β2GPI. Conclusion This proof-of-principle study confirms a role for complement in APS and opens the possibility of monitoring complement activation by including phospholipid vesicles in assay systems.

Original languageEnglish (US)
Pages (from-to)119-125
Number of pages7
JournalThrombosis Research
Volume156
DOIs
StatePublished - Aug 1 2017

Fingerprint

Antiphospholipid Syndrome
Complement Activation
Phospholipids
Glycoproteins
Thrombosis
Antiphospholipid Antibodies
Serum
Lectins
Systemic Lupus Erythematosus
Autoantibodies
Control Groups
Neoplasms

Keywords

  • Autoantibodies
  • Complement activation
  • Phospholipids
  • Thrombosis
  • Vascular endothelial cells

ASJC Scopus subject areas

  • Hematology

Cite this

A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome. / Rand, Jacob H.; Wu, Xiao Xuan; Wolgast, Lucia R.; Lei, Victor; Conway, Edward M.

In: Thrombosis Research, Vol. 156, 01.08.2017, p. 119-125.

Research output: Contribution to journalArticle

Rand, Jacob H. ; Wu, Xiao Xuan ; Wolgast, Lucia R. ; Lei, Victor ; Conway, Edward M. / A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome. In: Thrombosis Research. 2017 ; Vol. 156. pp. 119-125.
@article{ac0af812f43a412694256ae40ad8f617,
title = "A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome",
abstract = "Introduction The antiphospholipid syndrome (APS) is marked by autoantibodies that recognize anionic phospholipids in a cofactor-dependent manner. A role for complement has been implicated in the pathophysiology, however, elevations of complement activation markers have not been consistently demonstrated in clinical studies. We therefore designed a proof-of-principle study to determine whether complement activation might be detectable in APS by first exposing plasmas to phospholipid vesicles. Methods We examined complement activation markers in patients with APS, non-APS thrombosis, systemic lupus erythematosus, cancer, patients with antiphospholipid antibodies without thrombosis (APL) and healthy controls. Direct measurements of plasma C5a and sC5b-9 levels were compared to levels that were generated in normal serum by phospholipid vesicles that had been pre-incubated with the same plasmas. We then determined the effects of the C5 inhibitor, eculizumab, examined the complement pathways involved, and determined whether the effects could be reproduced with purified IgGs and β2-glycoprotein I (β2GPI). Results Plasma levels of C5a and sC5b-9 were higher, but not significantly increased in APS patients compared to healthy controls. In contrast, phospholipid vesicles pre-incubated with APS plasmas generated significantly higher levels than healthy controls and the other groups, except for APL patients. Complement activation was abrogated by addition of eculizumab. The results with substrate sera indicated that the alternative and classical/lectin pathways were involved. The results were reproducible with purified IgGs and β2GPI. Conclusion This proof-of-principle study confirms a role for complement in APS and opens the possibility of monitoring complement activation by including phospholipid vesicles in assay systems.",
keywords = "Autoantibodies, Complement activation, Phospholipids, Thrombosis, Vascular endothelial cells",
author = "Rand, {Jacob H.} and Wu, {Xiao Xuan} and Wolgast, {Lucia R.} and Victor Lei and Conway, {Edward M.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.thromres.2017.06.014",
language = "English (US)",
volume = "156",
pages = "119--125",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - A novel 2-stage approach that detects complement activation in patients with antiphospholipid antibody syndrome

AU - Rand, Jacob H.

AU - Wu, Xiao Xuan

AU - Wolgast, Lucia R.

AU - Lei, Victor

AU - Conway, Edward M.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Introduction The antiphospholipid syndrome (APS) is marked by autoantibodies that recognize anionic phospholipids in a cofactor-dependent manner. A role for complement has been implicated in the pathophysiology, however, elevations of complement activation markers have not been consistently demonstrated in clinical studies. We therefore designed a proof-of-principle study to determine whether complement activation might be detectable in APS by first exposing plasmas to phospholipid vesicles. Methods We examined complement activation markers in patients with APS, non-APS thrombosis, systemic lupus erythematosus, cancer, patients with antiphospholipid antibodies without thrombosis (APL) and healthy controls. Direct measurements of plasma C5a and sC5b-9 levels were compared to levels that were generated in normal serum by phospholipid vesicles that had been pre-incubated with the same plasmas. We then determined the effects of the C5 inhibitor, eculizumab, examined the complement pathways involved, and determined whether the effects could be reproduced with purified IgGs and β2-glycoprotein I (β2GPI). Results Plasma levels of C5a and sC5b-9 were higher, but not significantly increased in APS patients compared to healthy controls. In contrast, phospholipid vesicles pre-incubated with APS plasmas generated significantly higher levels than healthy controls and the other groups, except for APL patients. Complement activation was abrogated by addition of eculizumab. The results with substrate sera indicated that the alternative and classical/lectin pathways were involved. The results were reproducible with purified IgGs and β2GPI. Conclusion This proof-of-principle study confirms a role for complement in APS and opens the possibility of monitoring complement activation by including phospholipid vesicles in assay systems.

AB - Introduction The antiphospholipid syndrome (APS) is marked by autoantibodies that recognize anionic phospholipids in a cofactor-dependent manner. A role for complement has been implicated in the pathophysiology, however, elevations of complement activation markers have not been consistently demonstrated in clinical studies. We therefore designed a proof-of-principle study to determine whether complement activation might be detectable in APS by first exposing plasmas to phospholipid vesicles. Methods We examined complement activation markers in patients with APS, non-APS thrombosis, systemic lupus erythematosus, cancer, patients with antiphospholipid antibodies without thrombosis (APL) and healthy controls. Direct measurements of plasma C5a and sC5b-9 levels were compared to levels that were generated in normal serum by phospholipid vesicles that had been pre-incubated with the same plasmas. We then determined the effects of the C5 inhibitor, eculizumab, examined the complement pathways involved, and determined whether the effects could be reproduced with purified IgGs and β2-glycoprotein I (β2GPI). Results Plasma levels of C5a and sC5b-9 were higher, but not significantly increased in APS patients compared to healthy controls. In contrast, phospholipid vesicles pre-incubated with APS plasmas generated significantly higher levels than healthy controls and the other groups, except for APL patients. Complement activation was abrogated by addition of eculizumab. The results with substrate sera indicated that the alternative and classical/lectin pathways were involved. The results were reproducible with purified IgGs and β2GPI. Conclusion This proof-of-principle study confirms a role for complement in APS and opens the possibility of monitoring complement activation by including phospholipid vesicles in assay systems.

KW - Autoantibodies

KW - Complement activation

KW - Phospholipids

KW - Thrombosis

KW - Vascular endothelial cells

UR - http://www.scopus.com/inward/record.url?scp=85020844051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020844051&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2017.06.014

DO - 10.1016/j.thromres.2017.06.014

M3 - Article

VL - 156

SP - 119

EP - 125

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -